Paratek Pharmaceuticals (NASDAQ:PRTK) had its price target cut by analysts at HC Wainwright from $27.00 to $18.00 in a note issued to investors on Thursday, The Fly reports. The firm currently has a “buy” rating on the specialty pharmaceutical company’s stock. HC Wainwright’s target price would suggest a potential upside of 434.12% from the company’s previous close.

A number of other equities research analysts have also recently commented on the stock. ValuEngine raised shares of Paratek Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. BTIG Research set a $36.00 price objective on shares of Paratek Pharmaceuticals and gave the company a “sell” rating in a research note on Friday, November 1st. Finally, Zacks Investment Research cut shares of Paratek Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, October 24th. Two analysts have rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $18.92.

PRTK traded down $0.33 during trading on Thursday, hitting $3.37. The stock had a trading volume of 1,142,400 shares, compared to its average volume of 398,347. The company has a debt-to-equity ratio of 14.48, a quick ratio of 11.83 and a current ratio of 12.17. The firm has a market capitalization of $131.12 million, a P/E ratio of -0.94 and a beta of 1.74. The company’s 50-day moving average price is $3.65 and its 200 day moving average price is $3.99. Paratek Pharmaceuticals has a twelve month low of $2.66 and a twelve month high of $7.65.

Paratek Pharmaceuticals (NASDAQ:PRTK) last posted its quarterly earnings results on Tuesday, November 12th. The specialty pharmaceutical company reported ($1.00) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.06) by $0.06. Paratek Pharmaceuticals had a negative net margin of 597.22% and a negative return on equity of 459.96%. The business had revenue of $3.93 million for the quarter, compared to analysts’ expectations of $3.63 million. As a group, equities analysts expect that Paratek Pharmaceuticals will post -4.32 earnings per share for the current fiscal year.

In other Paratek Pharmaceuticals news, insider Randall B. Brenner sold 7,674 shares of the company’s stock in a transaction dated Thursday, October 3rd. The shares were sold at an average price of $3.98, for a total value of $30,542.52. Following the transaction, the insider now directly owns 91,338 shares in the company, valued at approximately $363,525.24. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Evan Loh sold 7,818 shares of the stock in a transaction dated Tuesday, October 8th. The stock was sold at an average price of $3.82, for a total transaction of $29,864.76. Following the transaction, the chief executive officer now owns 439,935 shares in the company, valued at $1,680,551.70. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 37,079 shares of company stock worth $145,472. 7.70% of the stock is owned by insiders.

Several hedge funds have recently made changes to their positions in the company. Northern Trust Corp increased its position in Paratek Pharmaceuticals by 1.1% during the 2nd quarter. Northern Trust Corp now owns 414,364 shares of the specialty pharmaceutical company’s stock worth $1,653,000 after purchasing an additional 4,517 shares in the last quarter. General American Investors Co. Inc. increased its position in Paratek Pharmaceuticals by 1.1% during the 2nd quarter. General American Investors Co. Inc. now owns 470,185 shares of the specialty pharmaceutical company’s stock worth $1,876,000 after purchasing an additional 5,200 shares in the last quarter. Bank of Montreal Can increased its position in Paratek Pharmaceuticals by 503.1% during the 2nd quarter. Bank of Montreal Can now owns 7,816 shares of the specialty pharmaceutical company’s stock worth $31,000 after purchasing an additional 6,520 shares in the last quarter. California Public Employees Retirement System increased its position in Paratek Pharmaceuticals by 5.8% during the 3rd quarter. California Public Employees Retirement System now owns 122,000 shares of the specialty pharmaceutical company’s stock worth $527,000 after purchasing an additional 6,700 shares in the last quarter. Finally, Citadel Advisors LLC increased its position in Paratek Pharmaceuticals by 7.2% during the 2nd quarter. Citadel Advisors LLC now owns 114,250 shares of the specialty pharmaceutical company’s stock worth $456,000 after purchasing an additional 7,639 shares in the last quarter. Institutional investors and hedge funds own 72.90% of the company’s stock.

Paratek Pharmaceuticals Company Profile

Paratek Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon biology and tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea.

Read More: Price to Earnings Ratio (PE)

The Fly

Analyst Recommendations for Paratek Pharmaceuticals (NASDAQ:PRTK)

Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.